Scarica l'app Stockscreener
137.75
0.93%
-1.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$138.99
Aprire:
$137.99
Volume 24 ore:
1.59M
Relative Volume:
0.23
Capitalizzazione di mercato:
$170.96B
Reddito:
$29.45B
Utile/perdita netta:
$8.51B
Rapporto P/E:
20.31
EPS:
6.7823
Flusso di cassa netto:
$9.46B
1 W Prestazione:
-1.73%
1M Prestazione:
-5.03%
6M Prestazione:
+16.49%
1 anno Prestazione:
+32.88%
Intervallo 1D:
$137.02
$139.55
Intervallo di 1 settimana:
$137.02
$142.97
Portata 52W:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
137.74 | 172.51B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
929.29 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
235.51 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
203.48 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
201.75 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
119.36 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-02-11 | Reiterato | Needham | Buy |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-08-19 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Aggiornamento | Truist | Hold → Buy |
| 2025-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
State of Alaska Department of Revenue Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Gilead (GILD), Tempus AI (TEM) Expand Multi-Year Oncology R&D Collaboration - Yahoo Finance
Sumitomo Mitsui Trust Group Reduces Gilead Sciences Stake - National Today
Greenup Street Wealth Management Boosts Gilead Sciences Stake - National Today
Greenup Street Wealth Management LLC Purchases Shares of 19,408 Gilead Sciences, Inc. $GILD - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $401.25 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Massachusetts Financial Firm Boosts Gilead Sciences Holdings - National Today
Massachusetts Financial Services Co. MA Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area - CSRwire
Gilead Sciences (GILD) to acquire Tubulis for $5B to strengthen oncology pipeline - MSN
Does Tempus AI’s (TEM) Deeper Gilead Tie Mark a Shift in Its Platform Strategy? - simplywall.st
Ritholtz Wealth Management Boosts Gilead Sciences Stake - National Today
Ritholtz Wealth Management Acquires 7,865 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s Tubulis Deal Recasts Oncology Ambitions And HIV Reliance Risks - Yahoo Finance
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Taxation With Representation: Goodwin, CMS, Wilson Sonsini - Law360
AHF Slams Gilead for Role in Florida AIDS Drug Crisis - Business Wire
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $175.00 - MarketBeat
Gilead projects $107M Q1 earnings headwind due to recent R&D deals - MSN
Cantor Fitzgerald Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $115.00 - MarketBeat
Gilead exercises option to license Kymera’s KT-200 - BioWorld News
Tempus AI stock rises on Gilead collaboration deal - Investing.com
Spirepoint Private Client LLC Has $9.37 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Tempus AI stock rises on Gilead collaboration deal By Investing.com - Investing.com South Africa
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders - Yahoo Finance
Rx Rundown: Gilead Sciences, Jeito Capital, Neurocrine Biosciences and more - Medical Marketing and Media
Why Is Tempus AI Stock Gaining Friday?Tempus AI (NASDAQ:TEM) - Benzinga
Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline - Yahoo Finance
Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - Investing News Network
Tempus AI expands collaboration with Gilead Sciences By Investing.com - Investing.com Australia
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines - MedCity News
Gilead Expands Tempus AI Partnership To Boost Oncology PipelineGilead Sciences (NASDAQ:GILD), Kymera T - Benzinga
Gilead Expands Oncology Pipeline With $5B Tubulis Deal - Yahoo Finance
Focus on HIV therapies propels Gilead Sciences stock consolidation amid mixed technical momentum - Traders Union
Gilead Sciences Sees Institutional Investment Boost - National Today
Gilead Sciences (GILD) Secures Exclusive Rights to KT-200 from K - GuruFocus
Gilead price target raised to $155 from $152 at Truist - Yahoo Finance
Tempus AI expands collaboration with Gilead Sciences - Investing.com
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE - Business Wire
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise - Business Wire
Gilead exercises option on Kymera’s CDK2 degrader for $45M By Investing.com - Investing.com India
OFI Invest Asset Management Acquires 470,804 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead exercises option on Kymera’s CDK2 degrader for $45M - Investing.com
MH & Associates Securities Management Corp ADV Invests $4.57 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate - The Manila Times
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 ... - Bluefield Daily Telegraph
8,451 Shares in Gilead Sciences, Inc. $GILD Bought by Jackson Square Capital LLC - MarketBeat
Hiltzik: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people - AOL.com
Germany: Gilead significantly expanding ADC capabilities with agreement to acquire Tubulis for up to US$5bn - Investors in Healthcare
Commentary: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people - Los Angeles Times
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):